SNAP-8
Aliases: Acetyl Octapeptide-3
Last verified: 2026-09-23
The short version
An extended Argireline analogue (octapeptide) — second-generation "topical Botox" with reportedly greater potency on wrinkle depth. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Manufacturer studies show ~35% wrinkle-depth reduction in 28 days; independent confirmation limited. Status: research chemical. Legal cosmetic ingredient.
Identity & type
- Molecular type
- peptide
- Origin
- An extended Argireline analogue (octapeptide) — second-generation "topical Botox" with reportedly greater potency on wrinkle depth.
Mechanism of action
Same as Argireline: SNARE-complex destabilization → reduced mimic-muscle contraction.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for SNAP-8. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Serums 3–10% 1–2× daily. Similar to Argireline with reportedly greater potency; a mild effect on expression lines is reported within 3–4 weeks.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Similar to Argireline with reportedly greater potency; a mild effect on expression lines is reported within 3–4 weeks.
Protocol — official vs community
Official / label
No approved protocol exists — investigational cosmetic ingredient. Acetyl octapeptide-3 is marketed topically in cosmetics; it was never the subject of a drug development program.
Duration: Continuous use while the product is applied; effects depend on continued application.
It is a legal cosmetic ingredient, which places it in a different regulatory and evidentiary category from the injectables in this database — but 'cosmetic ingredient' is not the same as 'validated'.
Community (anecdotal)
Serums at 3–10% SNAP-8 applied 1–2× daily to expression lines, per manufacturer-facing formulations. These percentages are commercial conventions, not trial-derived doses.
- Cycle:
- Continuous; ~28-day evaluation windows in the manufacturer studies.
- Break:
- None — effects fade within weeks of stopping, as with all mimic-relaxant topicals.
The ~35% wrinkle-depth reduction figure comes from manufacturer-sponsored studies; independent confirmation is limited. It is a mild, reversible, lower-efficacy cousin of Argireline — not 'topical Botox' in any literal sense.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Manufacturer studies show ~35% wrinkle-depth reduction in 28 days; independent confirmation limited.
Preclinical evidence
Manufacturer studies show ~35% wrinkle-depth reduction in 28 days; independent confirmation limited.
Known risks
- Rare irritation.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.